Skip to content
2000
Volume 4, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Simple determination of KA or KD values makes it possible to calculate the standard free energy DG° = - RTlnKA = RT lnKD (T= 298.15 K) of the binding equilibrium but not that of its two components as defined by the Gibbs equation DG° = DH° - TDS° where DH° and DS° are the equilibrium standard enthalpy and entropy, respectively. Recently, it has been shown that the relative DH° and DS° magnitudes can often give a simple “in vitro” way for discriminating “the effect”, that is the manner in which the drug interferes with the signal transduction pathways. This particular effect, called “thermodynamic discrimination”, results from the fact that binding of antagonists may be enthalpy-driven and that of agonists entropy-driven, or vice-versa. In the past, the thermodynamic discrimination was reported for the β-adrenergic G-protein-coupled receptor (GPCR) and confirmed later for adenosine A1, A2A and A3 receptors. Moreover, it has been found that the binding of all ligand-gated ion-channel receptors (LGICR) investigated was thermodynamically discriminated. In particular, affinity constants for typical neuronal nicotinic receptor ligands were obtained by both saturation and inhibition experiments with the radioligand [3H]-cytisine, a ganglionic nicotinic agonist. Thermodynamic parameters indicated that agonistic binding was both enthalpy- and entropy-driven, while antagonistic binding was totally entropy-driven. These results have shown that neuronal nicotinic receptor agonists and antagonists were thermodynamically discriminated. On these grounds, the thermodynamic behaviour makes it possible to discriminate drug pharmacological profiles in vivo through binding experiments in vitro.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026043451410
2004-01-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026043451410
Loading

  • Article Type:
    Review Article
Keyword(s): Anticancer Agents; methide-triperpenes; quinone
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test